Boston Scientific Corporation (BSX) Price Target Lowered at Mizuho Ahead of Q1 Medical Device Earnings

TheFly reported connected April 13 that Mizuho reduced its terms people connected BSX to $90 from $115 portion maintaining an Outperform rating. The accommodation was portion of a broader update crossed the firm’s aesculapian devices and diagnostics sum up of upcoming first-quarter earnings. The revisions bespeak updated estimates and outlook changes applied crossed aggregate companies wrong the aforesaid assemblage review.

According to a regulatory filing, connected March 30, Boston Scientific Corporation (NYSE:BSX) and Penumbra, Inc. each received a “Second Request” from the U.S. Federal Trade Commission arsenic portion of its antitrust reappraisal of their projected merger. The petition requires some companies to supply further information, extending the Hart-Scott-Rodino reappraisal timeline until 30 days aft afloat compliance, unless modified oregon concluded earlier by the agency.

The filing follows earlier submissions made by some firms successful mid-February nether modular regulatory procedures. Both companies stated they mean to respond promptly and proceed cooperating with the FTC passim the reappraisal process. The extended reappraisal period indicates ongoing regulatory scrutiny earlier immoderate last support determination is reached. The process is portion of the FTC’s modular valuation of ample transactions to measure imaginable competitory impacts wrong the healthcare and aesculapian exertion sector.

Boston Scientific Corporation (NYSE:BSX) is simply a planetary aesculapian instrumentality institution that develops and manufactures minimally invasive aesculapian technologies. It specializes successful interventional cardiology, bushed management, endoscopy, and urology solutions designed to amended diligent attraction and attraction outcomes.

While we admit the imaginable of BSX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest successful According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.